Login | Register

One Year On Herceptin For Breast Cancer Ideal

Patients in early-stage HER2-positive breast cancer should remain on Herceptin (trastuzumab) treatment for one year, and not two years or six months, according to a final analysis of the Phase III HERA trial, pharmaceutical company Roche and the Breast International Group announced today...

Read More

Leave a Reply

Your email address will not be published. Required fields are marked *